IGF-I and longevity

J. A. Janssen; S. W. Lamberts

doi:10.1159/000080508

IGF-I and longevity

J. A. Janssen^*
, S. W. Lamberts

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Review article › Academic › peer-review

25 Citations (Scopus)

Abstract

Recent animal studies have demonstrated evidence of the involvement of insulin and insulin-like growth factor (IGF)-I signalling in the control of ageing and longevity. Disruption of insulin/IGF-I signalling pathways significantly extends lifespan in several animal models. Similarities among these signalling pathways in animals and humans raise the possibility that modifications in the IGF-I signalling system could also extend lifespan in humans. However, in contrast to the findings in animal studies, reduced IGF-I activity in humans is not associated with longevity. In humans, low IGF-I activity is even associated with an increased risk of developing cardiovascular disease and diabetes. High IGF-I activity in humans is associated with an increased risk of developing cancer. In addition, genetic predisposition and lifestyle play a major role in determining age-associated disease. For each individual there is probably a specific optimal 'setpoint' for the insulin/growth hormone/IGF-I axis which co-determines survival. 2004 S. Karger AG, Basel.

Original language	English
Pages (from-to)	104-109
Number of pages	6
Journal	Hormone Research
Volume	62
Issue number	Suppl 3
DOIs	https://doi.org/10.1159/000080508
Publication status	Published - Oct 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1159/000080508

Cite this

@article{30fd8012a1724d53acc40a3817ea5dca,

title = "IGF-I and longevity",

abstract = "Recent animal studies have demonstrated evidence of the involvement of insulin and insulin-like growth factor (IGF)-I signalling in the control of ageing and longevity. Disruption of insulin/IGF-I signalling pathways significantly extends lifespan in several animal models. Similarities among these signalling pathways in animals and humans raise the possibility that modifications in the IGF-I signalling system could also extend lifespan in humans. However, in contrast to the findings in animal studies, reduced IGF-I activity in humans is not associated with longevity. In humans, low IGF-I activity is even associated with an increased risk of developing cardiovascular disease and diabetes. High IGF-I activity in humans is associated with an increased risk of developing cancer. In addition, genetic predisposition and lifestyle play a major role in determining age-associated disease. For each individual there is probably a specific optimal 'setpoint' for the insulin/growth hormone/IGF-I axis which co-determines survival. 2004 S. Karger AG, Basel.",

author = "Janssen, \{J. A.\} and Lamberts, \{S. W.\}",

year = "2004",

month = oct,

doi = "10.1159/000080508",

language = "English",

volume = "62",

pages = "104--109",

journal = "Hormone Research",

issn = "0301-0163",

publisher = "Karger",

number = "Suppl 3",

}

TY - JOUR

T1 - IGF-I and longevity

AU - Janssen, J. A.

AU - Lamberts, S. W.

PY - 2004/10

Y1 - 2004/10

N2 - Recent animal studies have demonstrated evidence of the involvement of insulin and insulin-like growth factor (IGF)-I signalling in the control of ageing and longevity. Disruption of insulin/IGF-I signalling pathways significantly extends lifespan in several animal models. Similarities among these signalling pathways in animals and humans raise the possibility that modifications in the IGF-I signalling system could also extend lifespan in humans. However, in contrast to the findings in animal studies, reduced IGF-I activity in humans is not associated with longevity. In humans, low IGF-I activity is even associated with an increased risk of developing cardiovascular disease and diabetes. High IGF-I activity in humans is associated with an increased risk of developing cancer. In addition, genetic predisposition and lifestyle play a major role in determining age-associated disease. For each individual there is probably a specific optimal 'setpoint' for the insulin/growth hormone/IGF-I axis which co-determines survival. 2004 S. Karger AG, Basel.

AB - Recent animal studies have demonstrated evidence of the involvement of insulin and insulin-like growth factor (IGF)-I signalling in the control of ageing and longevity. Disruption of insulin/IGF-I signalling pathways significantly extends lifespan in several animal models. Similarities among these signalling pathways in animals and humans raise the possibility that modifications in the IGF-I signalling system could also extend lifespan in humans. However, in contrast to the findings in animal studies, reduced IGF-I activity in humans is not associated with longevity. In humans, low IGF-I activity is even associated with an increased risk of developing cardiovascular disease and diabetes. High IGF-I activity in humans is associated with an increased risk of developing cancer. In addition, genetic predisposition and lifestyle play a major role in determining age-associated disease. For each individual there is probably a specific optimal 'setpoint' for the insulin/growth hormone/IGF-I axis which co-determines survival. 2004 S. Karger AG, Basel.

UR - https://www.scopus.com/pages/publications/21644476849

U2 - 10.1159/000080508

DO - 10.1159/000080508

M3 - Review article

C2 - 15539808

AN - SCOPUS:21644476849

SN - 0301-0163

VL - 62

SP - 104

EP - 109

JO - Hormone Research

JF - Hormone Research

IS - Suppl 3

ER -

IGF-I and longevity

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this